AnaptysBio, Inc., a San Diego, CA-based antibody development company, completed a $40m Series D financing round.
Participants included BVF Partners L.P. and its affiliates, BioMed Ventures, Cormorant Asset Management, Frazier Healthcare, HBM Healthcare Investments, Longwood Capital Partners, Novo A/S and additional undisclosed investors.
The company intends to use the funds to advance its anti-IL-33 and anti-IL-36 receptor antibody programs through key Phase II studies as well as support the continued discovery of novel therapeutic antibodies against emerging target biology in inflammation and immuno-oncology.
Led by Hamza Suria, President & CEO, AnaptysBio is focused on novel programs in immuno-oncology and inflammation. The company’s proprietary pipeline includes:
– ANB020, an anti-IL-33 antibody for the treatment of severe adult asthma and peanut allergy, and
– ANB019, an anti-IL-36 receptor antibody for the treatment of generalized pustular psoriasis.